Sinopep-Allsino Biopharmaceutical Co., Ltd.: FDA NDC listings

Does Sinopep-Allsino Biopharmaceutical Co., Ltd. list GLP-1 drug products with FDA?

Yes. FDA’s NDC Directory files, read Nov 15, 2026, list 10 products naming liraglutide, retatrutide, semaglutide and tirzepatide under the labeler name “Sinopep-Allsino Biopharmaceutical Co., Ltd.” and “Sinopep-Allsino Biopharmaceutical Co.,Ltd.”, in these marketing categories: BULK INGREDIENT (6); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (4). A listing is the labeler’s own submission; FDA says it does not indicate that FDA has verified the information or that the product is FDA-approved.

Labeler names in FDA’s files
Sinopep-Allsino Biopharmaceutical Co., Ltd.; Sinopep-Allsino Biopharmaceutical Co.,Ltd.
GLP-1 listings
10
Marketing categories
BULK INGREDIENT (6); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (4)
Drugs named
Liraglutide, Retatrutide, Semaglutide, Tirzepatide
Marketing start dates
Feb 1, 2019 to Sep 1, 2026

This page exists because the labeler has 2 or more compounded or bulk ingredient GLP-1 listings in FDA’s NDC files and no other page here under the same name. FDA’s NDC files give a labeler name, not an address or FEI number, so this index has not tied this labeler to any FDA inspection, letter or import record.

Listings

76177-018Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenLIRAGLUTIDEPOWDERNot given1 g/gBULK INGREDIENTFeb 1, 2019None givenDec 31, 2027Unfinished drugs
76177-118Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenLiraglutidePOWDERNot given1 kg/kgBULK INGREDIENTMar 1, 2019None givenDec 31, 2026Unfinished drugs
76177-520Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenLiraglutidePOWDERNot given1 kg/kgBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 1, 2019None givenDec 31, 2026Unfinished drugs
76177-055Sinopep-Allsino Biopharmaceutical Co.,Ltd.Not givenRetatrutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGSep 1, 2026None givenDec 31, 2027Unfinished drugs
76177-022Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTNov 1, 2023None givenDec 31, 2026Unfinished drugs
76177-054Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTMar 1, 2021None givenDec 31, 2026Unfinished drugs
76177-521Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 1, 2021None givenDec 31, 2027Unfinished drugs
76177-192Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJan 10, 2023None givenDec 31, 2026Unfinished drugs
76177-192Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJan 10, 2023None givenDec 31, 2027Unfinished drugs
76177-501Sinopep-Allsino Biopharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTNov 1, 2023None givenDec 31, 2026Unfinished drugs

FDA’s own words on the NDC Directory page (content current as of Mar 4, 2026):

Inclusion in the NDC Directory does not indicate that FDA has verified the information provided or that the products are FDA-approved. The content of each NDC Directory entry is the responsibility of the labeler submitting the SPL file. Assignment of an NDC number does not in any way denote FDA approval of the product. Any representation that creates an impression of FDA approval because a product has an NDC number is misleading and violates federal law. Inclusion in the NDC Directory or assignment of an NDC number does not mean a product is a drug as defined by federal law.

All GLP-1 NDC listings.

This page restates listings from FDA’s NDC Directory files as FDA publishes them. A listing is the labeler’s own submission to FDA, not an FDA approval and not a finding by this site, and it says nothing about inspections or enforcement. Follow the source link for FDA’s files. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.